Ethers

• 

  Subject Areas on Research

  • Absence of biochemical evidence for renal and hepatic dysfunction after 8 hours of 1.25 minimum alveolar concentration sevoflurane anesthesia in volunteers. 
  • Analysis of alkylphenol ethoxylate metabolites in the aquatic environment using liquid chromatography-electrospray mass spectrometry. 
  • Analysis of calcium homeostasis in activated human polymorphonuclear leukocytes. Evidence for two distinct mechanisms for lowering cytosolic calcium. 
  • Antimicrobial and bacteria-releasing multifunctional surfaces: oligo (p-phenylene-ethynylene)/poly (N-isopropylacrylamide) films deposited by RIR-MAPLE. 
  • Antimicrobial oligo(p-phenylene-ethynylene) film deposited by resonant infrared matrix-assisted pulsed laser evaporation. 
  • Application of ruthenium-induced macrocyclization for the construction of macrocyclic depsipeptides. 
  • Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity. 
  • Biotransformation of L-cysteine S-conjugates and N-acetyl-L-cysteine S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human kidney in vitro: interindividual variability in N-acetylation, N-deacetylation, and beta-lyase-catalyzed metabolism. 
  • Biotransformation of sevoflurane. 
  • Catalytic enantioselective alkylation of substituted dioxanone enol ethers: ready access to Calpha-tetrasubstituted hydroxyketones, acids, and esters. 
  • Clinical experience with substance P receptor (NK1) antagonists in depression. 
  • Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. 
  • Clinical sevoflurane metabolism and disposition. II. The role of cytochrome P450 2E1 in fluoride and hexafluoroisopropanol formation. 
  • Comparative absorption and bioaccumulation of polybrominated diphenyl ethers following ingestion via dust and oil in male rats. 
  • Comparison of Amsorb, sodalime, and Baralyme degradation of volatile anesthetics and formation of carbon monoxide and compound a in swine in vivo. 
  • Compound A uptake and metabolism to mercapturic acids and 3,3,3-trifluoro-2-fluoromethoxypropanoic acid during low-flow sevoflurane anesthesia: biomarkers for exposure, risk assessment, and interspecies comparison. 
  • Cytotoxicity of S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether (Compound A) in a human proximal tubular cell line. 
  • Dietary accumulation and metabolism of polybrominated diphenyl ethers by juvenile carp (Cyprinus carpio). 
  • Dose-dependent metabolism of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), an anesthetic degradation product, to mercapturic acids and 3,3,3-trifluoro-2-(fluoromethoxy)propanoic acid in rats. 
  • Effect of sevoflurane on P50 and on measurement of oxygen tension. 
  • Effects of ether and thiopental on spinal presynaptic terminals. 
  • Evidence for metabolism of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product, by cysteine conjugate beta-lyase. 
  • Gene expression profiling of nephrotoxicity from the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether ("compound A") in rats. 
  • Glutathione S-conjugation of the sevoflurane degradation product, fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human liver, kidney, and blood in vitro. 
  • Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. 
  • Identification in rat bile of glutathione conjugates of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether, a nephrotoxic degradate of the anesthetic agent sevoflurane. 
  • Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. 
  • Local deformation behavior of surface porous polyether-ether-ketone. 
  • Long-duration low-flow sevoflurane and isoflurane effects on postoperative renal and hepatic function. 
  • Low-flow sevoflurane compared with low-flow isoflurane anesthesia in patients with stable renal insufficiency. 
  • Metabolism and toxicity of the new anesthetic agents. 
  • Modified extraction procedure for gas-liquid chromatography applied to the identification of anaerobic bacteria. 
  • Multiple calcium-mediated effector mechanisms regulate chloride secretory responses in T84-cells. 
  • Myocardial ischemia and adverse cardiac outcomes in cardiac patients undergoing noncardiac surgery with sevoflurane and isoflurane. Sevoflurane Ischemia Study Group. 
  • Nephrotoxicity of sevoflurane compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether] in rats: evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjugate beta-lyase. 
  • Nonionic Ethoxylated Surfactants Induce Adipogenesis in 3T3-L1 Cells. 
  • Origins of the helical wrapping of phenyleneethynylene polymers about single-walled carbon nanotubes. 
  • P450-dependent and nonenzymatic human liver microsomal defluorination of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product. 
  • Pharmacovigilance and safety aspects of sevoflurane. 
  • Regio- and stereoselective synthesis of alkyl allylic ethers via gold(I)-catalyzed intermolecular hydroalkoxylation of allenes with alcohols. 
  • Regulation of inositol phosphate metabolism in chemoattractant-stimulated human polymorphonuclear leukocytes. Definition of distinct dephosphorylation pathways for IP3 isomers. 
  • Renal cysteine conjugate beta-lyase and compound A nephrotoxicity: minimal evidence for an association. 
  • Role of cytochrome P4503A in cysteine S-conjugates sulfoxidation and the nephrotoxicity of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in rats. 
  • Role of renal cysteine conjugate beta-lyase in the mechanism of compound A nephrotoxicity in rats. 
  • Role of the renal cysteine conjugate beta-lyase pathway in inhaled compound A nephrotoxicity in rats. 
  • Safety of low-flow sevoflurane anesthesia in patients with chronically impaired renal function is not proven. 
  • Serum levels of polybrominated diphenyl ethers (PBDEs) in foam recyclers and carpet installers working in the United States. 
  • Sevoflurane and halothane reduce focal ischemic brain damage in the rat. Possible influence on thermoregulation. 
  • Sevoflurane, fluoride ion, and renal toxicity. 
  • Spectrum and subcellular determinants of fluorinated anesthetic-mediated proximal tubular injury. 
  • Sulfoxidation of cysteine and mercapturic acid conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A). 
  • Supramolecular nanomimetics: replication of micelles, viruses, and other naturally occurring nanoscale objects. 
  • The hemodynamic and renal effects of sevoflurane and isoflurane in patients with coronary artery disease and chronic hypertension. Sevoflurane Ischemia Study Group. 
  • The regio- and stereospecific intermolecular dehydrative alkoxylation of allylic alcohols catalyzed by a gold(I) N-heterocyclic carbene complex. 
  • [Compound A: toxicology and clinical relevance]. 
• 

  Keywords of People

  • Warner, David Samuel, Distinguished Distinguished Professor of Anesthesiology, in the School of Medicine, Neurobiology